Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis

Hepatology

Volumn 26, Issue 4, 1997, Pages 1012-1017

  Rossini, Angelo ^a   Ravaggi, Antonella ^a   Biasi, Luciano ^a   Agostinelli, Enrica ^b   Bercich, Luisa ^a   Gazzola, Gian Battista ^b   Callea, Francesco ^a   Radaeli, Enrico ^a   Cariani, Elisabetta ^a,c  

^a General Hospital of Brescia   (Italy)

^b Hospital of Chiari   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AMINOTRANSFERASE; VIRUS RNA;

ARTICLE; CHRONIC HEPATITIS; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS CARRIER;

EID: 0030767766     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260432     Document Type: Article

References (29)

1. Zanetti A, Tanzi E, Zehender G, Magni E, Incarbone C, Zonaro A, Primi D, et al. Hepatitis C viras RNA in symptomless donors implicated in post-transfusion non-A, non-B hepatitis. Lancet 1990;336:448.
2. McGuinness PH, Bishop GA, Lien A, Wiley B, Parsons C, McCaughan GW. Detection of serum hepatitis C virus RNA in HCV antibody-seropositive volunteer blood donors. HEPATOLOGY 1993;18:485-490.
3. Rossini A, Gazzola GB, Ravaggi A, Agostinelli E, Biasi L, Albertini A, Radaeli E, et al. Long-term follow-up of and infectivity in blood donors with hepatitis C antibodies and persistently normal alanine aminotransferase levels. Transfusion 1995;35:108-111.
4. Esteban JI, Lopez-Talavera JC, Genesca J, Madoz P, Viladomiu L, Muniz E, Martin-Vega C, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991;115:443-449.
5. Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, Ruol A. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340:697-698.
6. Naito M, Hayashi N, Hagiwara H, Hiramatsu N, Kasahara A, Fusamoto H, Kamada T. Serum hepatitis C virus RNA quantity and histological features of hepatitis C viras carriers with persistently normal ALT levels. HEPATOLOGY 1994;19:871-875.
7. Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. HEPATOLOGY 1995;21:285-290.
8. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994;19:1513-1520.
9. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
10. Puoti M, Zonaro A, Ravaggi A, Marin MG, Castelnuovo F, Cariani E. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. HEPATOLOGY 1992;16:877-881
11. Ravaggi A, Zonaro A, Marin MG, Puoti M, Albertini A, Cariani E. Distribution of viral genotypes in Italy determined by hepatitis C virus typing by DNA immunoassay. J Clin Microbiol 1994;32:2280-2284.
12. Ravaggi A, Zonaro A, Mazza C, Albertini A, Cariani E. Quantification of hepatitis C virus RNA by competitive amplification of RNA from denatured serum and hybridization on microtiter plates. J Clin Microbiol 1995;33:265-269.
13. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
14. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrilo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
15. Tinè F, Magrin S, Craxî A, Pagliaro L. Interferon for chronic non-A, non-B hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991;13:192-199.
16. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, Kobayashi M, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. HEPATOLOGY 1991;13: 1040-1043.
17. Lau JYN, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-α in chronic hepatitis C. Lancet 1993;342:1208-1209.
18. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, Di Napoli A, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon α-2b. HEPATOLOGY 1993; 18:1300-1305.
19. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. HEPATOLOGY 1994;19:1088-1094.
20. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. HEPATOLOGY 1992;16:293-299.
21. Lau JYN, Davis GL, Kniffen J, Qian KE, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504.
22. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104: 877-883.
23. Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-β. HEPATOLOGY 1993;18:1319-1325.
24. Baron S, Tyring SK, Fleischmann WR, Coppenhauer DH, Niesel DW, Klimpel GR. The interferons. Mechanisms of action and clinical applications. JAMA 1991;266:1375-1383.
25. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15:82-91.
26. Serfaty L, Chazouillères O, Pawlotsky J-M, Andreani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996;110: 291-295.
27. Okada S-I, Akahane Y, Suzuki H, Okamoto H, Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. HEPATOLOGY 1992;16:619-624.
28. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. HEPATOLOGY 1994;20: 1121-1130.
29. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, Sato C. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. HEPATOLOGY 1995;22:30-35.